When does the patent expire on ibrance?

Short answer
The core patents that cover the active molecule palbociclib (Ibrance®) filed in the early 2000s will expire in the mid‑2020s (most in 2024‑2026). However, Pfizer still holds a number of “secondary” patents on formulations, delivery systems, and specific uses that run through the early 2030s. Because of that, the drug is still protected in the United States until around 2027–2032—generics are expected, if at all, to be launched in that window.

Why the dates differ

The 17‑year “patent term” that the FDA gives to new drugs is an additional protection that can extend the life of a drug beyond the 20‑year filing rule. For Ibrance, that extension pushes the final expiry to 2032.

What this means in practice

• No generics yet – As of 2026, no FDA‑approved generic version of Ibrance has entered the market. Generic manufacturers typically wait until all relevant patents have expired (or have been successfully challenged) before filing a “Abbreviated New Drug Application (ANDA).”

• Potential for a “generic window” – When the last of the “method‑of‑use” or “formulation” patents expires (likely 2027‑2028), there could be a window of about 3–4 years before the drug’s “patent term” (2032) runs out. During that period, multiple generic competitors might file ANDAs.

• Risk of “evergreening” – Pfizer may file new patents (e.g., new dosing schedules, new combination therapies, or new delivery devices) that could postpone generic entry further. This is a common industry practice known as “evergreening.”

How to stay updated

1. USPTO Patent Search – You can look up the specific patent numbers (e.g., US 7,987,823; US 8,040,447; US 9,242,444) in the USPTO database to confirm filing and expiry dates.

2. FDA Orange Book – The FDA’s “Orange Book” lists all active patents and exclusivities for a drug, and is updated annually.

3. Industry news – Press releases from Pfizer and generic manufacturers often announce ANDA filings or anticipated launch dates.

Bottom line

• Core patents: expire 2024‑2026.
• Secondary patents: expire 2027‑2032.
• Generic entry: most likely in the late 2020s (2027‑2029) if no additional patents are granted.

Feel free to let me know if you’d like help checking a specific patent number or the latest FDA Orange Book entry for Ibrance!